AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Quarter Return
+9.75%
1 Year Return
+18.84%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$135M
AUM Growth
+$135M
(-0.95%)
Cap. Flow
-$14.5M
Cap. Flow
% of AUM
-10.77%
Top 10 Holdings %
Top 10 Hldgs %
21.49%
Holding
245
New
28
Increased
32
Reduced
137
Closed
15
Top Buys
| 1 |
Merck
MRK
|
$2.73M |
| 2 |
Indivior
INDV
|
$2.36M |
| 3 |
Alphatec Holdings
ATEC
|
$2.06M |
| 4 |
Neurocrine Biosciences
NBIX
|
$1.79M |
| 5 |
Apellis Pharmaceuticals
APLS
|
$1.37M |
Top Sells
| 1 |
BioCryst Pharmaceuticals
BCRX
|
$4.17M |
| 2 |
Pacira BioSciences
PCRX
|
$3.36M |
| 3 |
Pfizer
PFE
|
$3.04M |
| 4 |
United Therapeutics
UTHR
|
$2.96M |
| 5 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$2.13M |
Sector Composition
| 1 | Healthcare | 57.92% |
| 2 | Real Estate | 14.45% |
| 3 | Financials | 7.05% |
| 4 | Industrials | 3.2% |
| 5 | Technology | 2.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Enact Holdings
ACT
$5.57B
| $1.54M | 1.14% |
42,367
| – | – |
|
27
Equity Lifestyle Properties
ELS
$11.7B
| $1.47M | 1.09% |
20,611
| – | – |
|
|
ITCI
28
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $1.46M | 1.09% |
20,000
| – | – |
|
29
Amphastar Pharmaceuticals
AMPH
$1.37B
| $1.46M | 1.08% |
30,000
+5,000
| +20% | +$243K |
|
|
VRNA
30
Verona Pharma
VRNA
$9.18B
| $1.44M | 1.07% |
50,000
-6,000
| -11% | -$173K |
|
31
GSK
GSK
$79.3B
| $1.43M | 1.06% |
35,000
| – | – |
|
|
32
Apellis Pharmaceuticals
APLS
$3.51B
| $1.37M | 1.02% |
+47,500
| New | +$1.37M |
|
|
NYMT
33
New York Mortgage Trust
NYMT
$642M
| $1.27M | 0.95% |
200,963
| – | – |
|
|
RVNC
34
DELISTED
Revance Therapeutics, Inc.
RVNC
| $1.27M | 0.95% |
245,000
| – | – |
|
|
ONC
35
BeOne Medicines Ltd. American Depositary Shares
ONC
$37B
| $1.23M | 0.92% |
5,500
-9,500
| -63% | -$2.13M |
|
36
Stereotaxis
STXS
$246M
| $1.22M | 0.91% |
600,000
| – | – |
|
37
Enovis
ENOV
$1.75B
| $1.18M | 0.88% |
27,500
+7,500
| +38% | +$323K |
|
38
Roivant Sciences
ROIV
$8.6B
| $1.15M | 0.86% |
100,000
+12,000
| +14% | +$138K |
|
39
Structure Therapeutics
GPCR
$1.14B
| $1.14M | 0.85% |
26,000
| – | – |
|
40
Takeda Pharmaceutical
TAK
$47.8B
| $1.14M | 0.85% |
+80,000
| New | +$1.14M |
|
41
Protagonist Therapeutics
PTGX
$3.62B
| $1.13M | 0.84% |
25,000
| – | – |
|
42
Perspective Therapeutics
CATX
$251M
| $1.07M | 0.79% |
80,000
-2,000
| -2% | -$26.7K |
|
43
Celldex Therapeutics
CLDX
$1.57B
| $1.02M | 0.76% |
30,000
-17,500
| -37% | -$595K |
|
|
44
Pfizer
PFE
$141B
| $1.01M | 0.75% |
35,000
-105,000
| -75% | -$3.04M |
|
45
Sanofi
SNY
$122B
| $1.01M | 0.75% |
17,500
| – | – |
|
46
Immunovant
IMVT
$2.91B
| $998K | 0.74% |
35,000
-1,500
| -4% | -$42.8K |
|
47
Lantheus
LNTH
$3.75B
| $988K | 0.73% |
+9,000
| New | +$988K |
|
48
Axsome Therapeutics
AXSM
$6.09B
| $944K | 0.7% |
10,500
-4,500
| -30% | -$404K |
|
49
Karyopharm Therapeutics
KPTI
$61.4M
| $934K | 0.69% |
1,125,000
| – | – |
|
50
AGNC Investment
AGNC
$10.4B
| $885K | 0.66% |
84,646
| – | – |
|